Comments on reasons for third-party review pilot's unpopularity sought by FDA in letter to industry.
This article was originally published in The Gray Sheet
Executive Summary
FDA SEEKING COMMENTS ON THIRD-PARTY REVIEW PILOT "LOW UTILIZATION" through a letter on the pilot sent to third parties and device trade groups during the week of Nov. 18. Calling for comments by Dec. 15, the agency asks respondents to discuss "factors that may account for the industry's low utilization of the pilot program to date."
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.